

# CANCER GENOMICS & PROTEOMICS

online from January 2009  
 HighWire Press®  STANFORD UNIVERSITY

www.cgp-journal.com

Print ISSN: 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004) - VOL. 2 (2005) - VOL. 3 (2006)

VOL. 4 (2007) - VOL. 5 (2008) - VOL. 6 (2009)

**General Policy.** CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 2-4 months from submission or 1-2 months from acceptance.

Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services: PUBMED, \*<sup>o</sup>DLINE, CAS (Chemical Abstracts Service); BIOLOGICAL ABSTRACTS; EMBASE and BIOBASE, Compendex, GEOBASE, EMBiology, FLUIDEX, Scopus (Elsevier Bibliographic Databases); BIOSIS PREVIEWS; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal, PubsHub, SIIC.

## Editorial Office: International Institute of Anticancer Research

1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece.

Tel: +30 22950 52945, Fax: +30 22950 53389

e-mail: journals@iiar-anticancer.org (Editorial Office); editor@iiar-anticancer.org, editor@cgp-journal.com (Managing Editor)

### A Selection of Recent Papers

Proteomic Analysis of Archival Breast Cancer Serum. B.A ZEIDAN, R.I. CUTRESS, N. MURRAY, G. COULTON, C. HASTIE, G. PACKHAM, P.A. TOWNSEND (*Southampton; Gosport; London; Portsmouth, UK*)

MicroRNA-222 Regulates Cell Invasion by Targeting Matrix Metalloproteinase 1 (MMP1) and Manganese Superoxide Dismutase 2 (SOD2) in Tongue Squamous Cell Carcinoma Cell Lines. X. LIU, J. YU, L. JIANG, A. WANG, F. SHI, H. YE, X. ZHOU (*Chicago, IL, USA; Guangzhou, China*)

Increased levels of macrophage-secreted Cathepsin S during prostate cancer progression in TRAMP mice and patients. C. LINDAHL, M. SIMONSSON, A. BERGH, E. THYSELL, H. ANTTI, M. SUND, P. WIKSTRÖM (*Umeå, Sweden*)

Effect of Expressional Alteration of KAI1 on Breast Cancer Cell Growth, Adhesion, Migration and Invasion. F.A. MALIK, A.J SANDERS, M.A. KAYANI, W.G. JIANG (*Cardiff, Wales, UK; Islamabad, Pakistan*)

Gene Expression Profiling in Response to Estradiol and Genistein in Ovarian Cancer Cells. L. P. PARKER, D.D. TAYLOR, S. KERSTERSON, C. GERCEL-TAYLOR (*Louisville KY, USA*)

Differences in mRNA and microRNA Microarray Expression Profiles in Human Colon Adenocarcinoma HT-29 Cells Treated with either Intensity-modulated Radiation Therapy (IMRT), or Conventional Radiation Therapy (RT). F.E. AHMED, P.W. VOS, C. JEFFRIES, J.E. WILEY, D.A. WEIDNER, H. MOTA, C. BONNERUP (*Greenville; Chapel Hill, NC, USA*)

Chromosomal Alterations and Mutagen Sensitivity in Human Mucosal Cells of the Oropharynx and Lymphocytes caused by BPDE. M. REITER, P. BAUMEISTER, S. ZIEGER, U. HARRÉUS (*Munich, Germany*)

Pathogenetic and Clinical Relevance of MicroRNAs in Colorectal Cancer. N. VALERI, C.M. CROCE, M. FABBRI (*Columbus, OH, USA; Ferrara; Meldola, Italy*)

PGF Isoforms, PLGF-1 and PGF-2, in Colorectal Cancer and the Prognostic Significance. A. ESCUDERO-ESPARZA, T.A. MARTIN, M.L. DAVIES, W.G. JIANG (*Cardiff, UK*)

MGMT Promoter Hypermethylation in a Series of 104 Glioblastomas. M. MELLAI, V. CALDERA, L. ANNOVAZZI, A. CHIÒ, M. LANOTTE, P. CASSONI, G. FINOCCHIARO, D. SCHIFFER (*Turin; Milan, Italy*)

Gene Expression Analysis of HCT116 Colon Tumor Derived Cells Treated with the Polyamine Analog PG-11047. N.A. IGNATENKO H.F. YERUSHALMI, R. PANDEY, K.L. KACHEL, D.E. STRINGER, L.J. MARTON, E.W. GERNER (*Tucson, AZ; Redwood City, CA, USA; Haifa, Israel*)

Diagnosis of Breast Cancer by Tear Proteomic Pattern. A. LEBRECHT, D. BOEHM, M. SCHMIDT, H. KOELBL, R.L. SCHWIRZ, F.H. GRUS (*Mainz, Germany*)

## Instructions to Authors

*General Policy.* ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

*NIH Open Access Policy.* The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

*Copyright.* Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

*Format.* Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

*Manuscripts.* Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

*Figures.* All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

*Tables.* Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

*Nomenclature and Abbreviations.* Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

*References.* Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

*Clinical Trials.* Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

*Submission of Manuscripts.* Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice.):

1. To submit your article online please visit: IAR-Submissions (<http://www.iar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to [journals@iar-anticancer.org](mailto:journals@iar-anticancer.org). Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (\*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:

John G. Delinassios

International Institute of Anticancer Research (IAR)  
Editorial Office of ANTICANCER RESEARCH,  
IN VIVO, CANCER GENOMICS and PROTEOMICS.  
1st km Kapandritiou-Kalamou Road  
P.O. Box 22, GR-19014 Kapandriti, Attiki  
GREECE

Submitted articles will not be returned to Authors upon rejection.

*Galley Proofs.* Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

*Reprints.* Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2009 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

online from January 2009



**in vivo**

International Journal of Experimental and Clinical  
Pathophysiology and Drug Research

Published by the International Institute of Anticancer Research

ISSN: 0258-851X

### General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the aims and the research programmes of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

### Editorial Office

Manuscripts and correspondence should be addressed to: Dr. J.G. Delinassios, Managing Editor, IN VIVO Editorial Office, International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389. e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IAR and the conferences please visit the IAR website: [www.iiar-anticancer.org](http://www.iiar-anticancer.org)

### Selection of Recent Articles

Circulating Cytokine Levels In Prostate Cancer Patients Undergoing Radiation Therapy: Influence Of Neoadjuvant Total Androgen Suppression. R.M. JOHNKE J.M. EDWARDS, M.J. EVANS, G.N. NANGAMI, N.T.G. BAKKEN, J.M. KILBURN, T.-K. LEE, R.R. ALLISON, U.L. KARLSSON, H.H. ARASTU (*Greenville, NC, USA*)

Transgenic Mice Expressing Constitutively Active Akt in Oral Epithelium Validate Klf4 as a Potential Biomarker of Head and Neck Squamous Cell Carcinoma. M. MORAL, C. SEGRELLES, A.B. MARTÍNEZ-CRUZ, C. LORZ, *et al.* (*Madrid, Spain; Smithville, TX, USA*)

Detection of Herpesviruses and Parvovirus B19 in Gastric and Intestinal Mucosa of Chronic Fatigue Syndrome Patients. M. FRÉMONT, K. METZGER, H. RADY, J. HULSTAERT, K. DE MEIRLEIR (*Zellik; Brussels; Vilvoorde, Belgium*)

A Bioluminescent Orthotopic Mouse Model of Human Osteosarcoma that Allows Sensitive and Rapid Evaluation of New Therapeutic Agents In Vivo. K.E. COMSTOCK, C.L. HALL, S. DAIGNAULT, S.A. MANDLEBAUM, C. YU, E.T. KELLER (*Ann Arbor, MI, USA*)

Obesity Impairs Wound Healing in Ovariectomized Female Mice. V.B. HOLCOMB, V.A. KECK, J.C. BARRETT, J. HONG, S.K. LIBUTTI, N.P. NÚÑEZ (*Austin, TX; Bethesda, MD; Cambridge, MA; Bronx, NY, USA*)

Effectiveness of Combined Modality Radiotherapy of Orthotopic Human Squamous Cell Carcinomas in Nu/Nu Mice Using Cetuximab, Tirapazamine, and MnSOD-Plasmid Liposome Gene Therapy. M.W. EPPERLY, S.M. LAI, N. MASON, B. LOPRESI, T. DIXON, D. FRANICOLA, Y. NIU, W.R. WILSON, A.J. KANAI, J.S. GREENBERGER (*Pittsburgh, PA, USA; Auckland, New Zealand*)

Inhibiting Platelet Derived Growth Factor Beta (PDGFR-B) Decreases Ewing's Sarcoma Growth and Metastasis in a Novel Orthotopic Human Xenograft Model. Y.X. WANG, D. MANDAL, S. WANG, D. HUGHES, R.E. POLLOCK, D. LEV, E. KLEINERMAN, A. HAYES-JORDAN (*Houston, TX; Kingston, RI, USA*)

Ethyl-eicosapentaenoic Acid Reduces Liver Lipids and Lowers Plasma Levels of Lipids in Mice fed a High-fat Diet. N. NEMOTO, S. SUZUKI, H. KIKUCHI, H. OKABE, S. SASSA, S. SAKAMOTO (*Chiba; Tokyo, Japan*)

Management of Pseudomyxoma Peritonei by Cytoreduction+HIPEC (Hyperthermic Intraperitoneal Chemotherapy): Results Analysis of a Twelve-Year Experience. M. VAIRA, T. CIOPPA, G. DE MARCO, C. BING, S. D'AMICO, M. D'ALESSANDRO, G. FIORENTINI, M. DE SIMONE (*Florence; Italy*)

Dietary Calcium Source Influences Body Composition, Glucose Metabolism and Hormone Levels in a Mouse Model of Postmenopausal Obesity. R.E. DE ANGEL, D. BERRIGAN, N.P. NÚÑEZ, S.D. HURSTING, S.N. PERKINS (*Austin; Smithville, TX; Bethesda, MD, USA*)

Distribution of [<sup>3</sup>H]-Corticosterone in Urine, Feces and Blood of Male Sprague-Dawley Rats After Tail Vein and Jugular Vein Injections. K.S.P. ABELSON, S.S. FARD, J. NYMAN, R. GOLDKUHL, J. HAU (*Uppsala, Sweden; Copenhagen, Denmark*)

5-Hydroxymethylfurfural and 5-Sulfooxymethylfurfural Increase Adenoma and Flat ACF Number in the Intestine of Min/+ Mice. C. RÖNNINGBORG, T. HUS-Y, H. GLATT, J.E. PAULSEN, J. ALEXANDER (*Oslo, Norway; Nuthetal, Germany*)

Ocular Toxicity Caused by Paclitaxel in Neonatal Sprague-Dawley Rats. M. KUWATA, K. YOSHIZAWA, M. MATSUMURA, K. TAKAHASHI, A. TSUBURA (*Osaka, Japan*)

**FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST**

The BB Genotype of <i>Heat-shock Protein (HSP) 70-2</i> Gene Is Associated with Gastric Pre-malignant Condition in <i>H. pylori</i> -infected Older Patients. T. TAHARA, T. SHIBATA, T. ARISAWA, M. NAKAMURA, D. YOSHIOKA, M. OKUBO, N. MARUYAMA, T. KAMANO, Y. KAMIYA, H. FUJITA, M. NAGASAKA, M. IWATA, H. YAMASHITA, H. NAKANO, I. HIRATA ( <i>Aichi; Ishikawa, Japan</i> ) .....	3453
Preliminary Study of Detecting Urothelial Malignancy with FDG PET in Taiwanese ESRD Patients. S.-S. SUN, C.-H. CHANG, H.-J. DING, C.-H. KAO, H.-C. WU, T.-C. HSIEH ( <i>Taichung; Kaohsiung, Taiwan, ROC</i> ).....	3459
Serum and Tissue Selenium Levels in Gastric Cancer Patients and Correlation with CEA. K. CHARALABOPOULOS, A. KOTSALOS, A. BATISTATOU, A. CHARALABOPOULOS, D. PESCHOS, P. VEZYRAKI, V. KALFAKAKOU, A. METSIOS, A. CHARALAMPOPOULOS, A. MACHERAS, N. AGNANTIS, A. EVANGELOU ( <i>Ioannina; Athens, Greece</i> ).....	3465
* Reviews (pages 3289, 3353)	

A Novel <i>K-ras</i> Mutation in Colorectal Cancer. A Case Report and Literature Review. R. PALMIROTTA, A. SAVONAROLA, V. FORMICA, G. LUDOVICI, G. DEL MONTE, M. ROSELLI, F. GUADAGNI ( <i>Rome, Italy</i> ) .....	3369
Clinicopathological and Immunohistochemical Characteristics of Esophageal Carcinosarcoma. A. SANO, S. SAKURAI, H. KATO, M. SAKAI, N. TANAKA, T. INOSE, K. SAITO, M. SOHDA, M. NAKAJIMA, K. SAKAMOTO, T. SANO, Y. HOSOYA, T. ENOMOTO, T. KANDA, Y. AJIOKA, T. OYAMA, H. KUWANO ( <i>Gunma; Tochigi; Niigata, Japan</i> ) .....	3375
Image-guided Robotic Stereotactic Radiosurgery for Unresectable Liver Metastases: Preliminary Results. G. AMBROSINO, F. POLISTINA, G. COSTANTIN, P. FRANCESCON, R. GUGLIELMI, P. ZANCO, F. CASAMASSIMA, A. FEBBRARO, G. GERUNDA, F. LUMACHI ( <i>Padova; Vicenza; Firenze; Benevento; Modena, Italy</i> ) .....	3381
Feasibility Study of S-1 plus Weekly Docetaxel Combined with Concurrent Radiotherapy in Advanced Gastric Cancer Refractory to First-line Chemotherapy. K. FUJITANI, T. TSUJINAKA, H. YAMASAKI, M. HIRAO, K. YOSHIDA, Y. KUROKAWA ( <i>Osaka, Japan</i> ) .....	3385
Background, Reasons and Benefits Using the Vienna Protocol for the Treatment of Painful Bone Recurrences with <sup>153</sup> Samarium-EDTMP. H. SINZINGER, K. WEISS, J. HILTUNEN ( <i>Vienna; Neustadt, Austria</i> ) .....	3393
Kidney-autotransplantation before Radiotherapy: A Case Report. T. BÖLLING, K. JANKE, H.H. WOLTERS, M. GLASHÖRSTER, I. ERNST, N. WILLICH, J. BROCKMANN, S. KÖNEMANN ( <i>Münster, Germany</i> ) .....	3397
Comparison of Cytology, Colposcopy, HPV Typing and Biomarker Analysis in Cervical Neoplasia. M. ADAMOPOULOU, E. KALKANI, E. CHARVALOS, D. AVGOUSTIDIS, D. HAIDOPOULOS, C. YAPIJAKIS ( <i>Athens, Greece</i> ) .....	3401
Extrapulmonary Small Cell Carcinoma (EPSCC): 10 Years' Multi-disciplinary Experience at Charite. S. OCHSENREITHER, S. MARNITZ-SCHULTZE, A. SCHNEIDER, C. KOEHLER, S. DAUM, C. LODDENKEMPER, V. BUDACH, E. THIEL, U. KEILHOLZ, A. SCHMITTEL ( <i>Berlin, Germany</i> ) .....	3411
Influence of KGF on the Progression of Pancreatic Cancer. X.-P. ZANG, M. LERNER, D. BRACKETT, J.T. PENTO ( <i>Oklahoma City, OK, USA</i> ) .....	3417
Cyfra 21-1 as a Serum Tumor Marker for Follow-up of Patients with Laryngeal and Hypopharyngeal Squamous Cell Carcinoma. H. AL-SHAGAHIN, K. ALKOTYFAN, H.-H. MÜLLER, A.M. SESTERHENN, J.A. WERNER ( <i>Marburg, Germany</i> ) .....	3421
A Comparison of Stage of Presentation for Pancreatic and Colorectal Cancer in Pennsylvania 2000-2005. M. CHIRUMBOLE, N. GUSANI, A. HOWARD, T. LEONARD, P. LEWIS, J. MUSCAT ( <i>Hershey, PA, USA</i> ) .....	3427
Efficiency of Iloprost Treatment for Chemotherapy-associated Osteonecrosis after Childhood Cancer. M. JÄGER, C. ZILKENS, B. WESTHOFF, E.M. JELINEK, G. KOZINA, R. KRAUSPE ( <i>Düsseldorf, Germany</i> ) .....	3433
Docetaxel plus Gemcitabine as First-line Treatment in Malignant Pleural Mesothelioma: A Single Institution Phase II Study. M. RALLI, I. TOURKANTONIS, N. MAKRILIA, E. GKINI, E. KOTTEAS, I. GKIOZOS, N. KATIRTZOGLU, K. SYRIGOS ( <i>Athens, Greece</i> ) .....	3441
Clinicopathological Characteristics of Recurrence More than 10 Years after Surgery in Patients with Breast Carcinoma. H. TAKEUCHI, Y. MUTO, H. TASHIRO ( <i>Beppu; Oita, Japan</i> ) .....	3445
The AA Genotype of a <i>L1C</i> G842A Polymorphism Is Associated with an Increased Risk for Ovarian Cancer. M. HEUBNER, P. WIMBERGER, S. KASIMIR-BAUER, F. OTTERBACH, R. KIMMIG, W. SIFFERT ( <i>Duisburg-Essen, Germany</i> ) .....	3449

First Experiences with Low-dose Anti-angiogenic Treatment in Gliomatosis Cerebri with Signs of Angiogenic Activity. M. SEIZ, P. KOHLHOF, M.A. BROCKMANN, E. NEUMAIER-PROBST, P. HERMES, A. VON DEIMLING, P. VAJKOCZY, K. SCHMIEDER, J. TUETTENBERG ( <i>Heidelberg; Berlin, Germany</i> ) .....	3261
Prognostic Impact of CD68 and Kallikrein 6 in Human Glioma. T. STROJNIK, R. KAVALAR, I. ZAJC, E.P. DIAMANDIS, K. OIKONOMOPOULOU, T.T. LAH ( <i>Maribor; Ljubljana, Slovenia; Toronto, ON, Canada</i> ) .....	3269
Tandem High-dose Chemotherapy Followed by Autologous Transplantation in Patients with Locally Advanced or Metastatic Sarcoma. A. LASHKARI, W.A. CHOW, F. VALDES, L. LEONG, V. PHAN, P. TWARDOWSKI, N. KAPOOR, A. MOLINA, Z. AL-KADHIMI, P. FRANKEL, G. SOMLO ( <i>Duarte, CA, USA</i> ) .....	3281
* Review: New Molecular Biomarkers for the Prognosis and Management of Prostate Cancer – The Post PSA Era. B. BICKERS, C. AUKIM-HASTIE ( <i>Portsmouth, Hampshire, UK</i> ) .....	3289
Analysis of Factors Influencing Dysphagia Severity Following Treatment of Head and Neck Cancer. N.P. NGUYEN, C. FRANK, C.C. MOLTZ, U. KARLSSON, P.D. NGUYEN, H.W.C. WARD, P. VOS, H.J. SMITH, S. HUANG, L.M. NGUYEN, C. LEMANSKI, A. LUDIN, S. SALLAH ( <i>Tucson, AZ; Dallas, TX; Greenville, NC; Ann Arbor, MI; Cleveland, OH, USA; Montpellier, France; Athens, Greece</i> ) .....	3299
Induction of Severe Cataract and Late Renal Dysfunction Following Total Body Irradiation: Dose–Effect Relationships. H.B. KAL, M.L. VAN KEMPEN-HARTEVELD ( <i>Utrecht, The Netherlands</i> ) .....	3305
The Angiogenic Growth Factors HGF and VEGF in Serum and Plasma from Neuroblastoma Patients. E.G. SKÖLDENBERG, A. LARSSON, Å. JAKOBSON, F. HEDBORG, P. KOGNER, R.H. CHRISTOFFERSON, F. AZARBAYJANI ( <i>Uppsala; Stockholm, Sweden</i> ) .....	3311
Prognostic Significance of Serum Adipokine Levels in Colorectal Cancer Patients. F. GUADAGNI, M. ROSELLI, F. MARTINI, A. SPILA, S. RIONDINO, R. D’ALESSANDRO, G. DEL MONTE, V. FORMICA, A. LAUDISI, I. PORTARENA, R. PALMIROTTA, P. FERRONI ( <i>Rome, Italy</i> ) .....	3321
Placement of an Expandable Metallic Stent Improves the Efficacy of Chemoradiotherapy for Pancreatic Cancer with Malignant Portal Vein Stenosis or Obstruction. Y. NIO, C. IGUCHI, M. ITAKURA, T. NISHI, K. HASHIMOTO, H. TAKEDA, M. TAKAMURA, H. OMORI, Y. SATO, M. KOIKE, S.-I. ENDO ( <i>Kyoto; Shimane; Hyogo, Japan</i> ) .....	3329
Effect of Aromatase Inhibitors on Lipid Metabolism, Inflammatory Response and Antioxidant Balance in Patients with Breast Carcinoma. B. MELICHAR, H. KALÁBOVÁ, L. KRČMOVÁ, L. URBÁNEK, R. HYŠPLER, D. SOLICHOVÁ, K. MELICHAROVÁ, M. PECKA, Z. ZADÁK ( <i>Hradec Králové; Olomouc, Czech Republic</i> ) .....	3337
Frequency of Lymph Node Metastasis to the Splenic Hilus and Effect of Splenectomy in Proximal Gastric Cancer. S. SASADA, M. NINOMIYA, M. NISHIZAKI, M. HARANO, Y. OJIMA, H. MATSUKAWA, H. AOKI, S. SHIOZAKI, S. OHNO, N. TAKAKURA ( <i>Hiroshima, Japan</i> ) .....	3347
* Review: Current and Future Options in the Treatment of Malignant Ascites in Ovarian Cancer. H. WOOPEN, J. SEHOULI ( <i>Berlin, Germany</i> ) .....	3353
MRSA-pyomyositis in a Patient with Acute Myelogenous Leukemia after Intensive Chemotherapy. T. FUKUSHIMA, H. IWAO, A. NAKAZIMA, M. MIKI, T. SAKAI, T. SAWAKI, M. TANAKA, Y. MASAKI, Y. HIROSE, H. UMEHARA ( <i>Ishikawa, Japan</i> ) .....	3361
Texture Image Analysis in Differentiating Malignant from Benign Adrenal Cortical Tumors in Children and Adults. N.K. SHIRATA, S.T. SREDNI, A. CASTELO, A. SANTINELLI, B. MENDONÇA, R. MONTIRONI, A. LONGATTO FILHO, M.C.N. ZERBINI ( <i>São Paulo, Brazil; Chicago, IL, USA; Ancona, Italy; Braga, Portugal</i> ) .....	3365

Phagocytosis of Cancer Cells by Mast Cells in Breast Cancer. F. DELLA ROVERE, A. GRANATA, M. MONACO, G. BASILE ( <i>Messina, Italy</i> ) .....	3157
Effects of Tetrandrine plus Radiation on Neuroblastoma Cells. Y. CHEN, J.-C. CHEN, S.-H. TSENG ( <i>Taipei; Taoyuan; Chia-Yi, Taiwan, ROC</i> ) .....	3163
Combination Chemotherapy of Nafamostat Mesilate with Gemcitabine for Pancreatic Cancer Targeting NF- $\kappa$ B Activation. T. UWAGAWA, P.J. CHIAO, T. GOCHO, S. HIROHARA, T. MISAWA, K. YANAGA ( <i>Tokyo, Japan; Houston, TX, USA</i> ) .....	3173
Effect of Free Radicals on the Biological Action of Genistein <i>In Vitro</i> and Synergism with Mitomycin C.J. HARTMANN, N. GETOFF ( <i>Vienna, Austria</i> ) .....	3179
Curcumin Inhibits Proliferation of Colorectal Carcinoma by Modulating Akt/mTOR Signaling. S.M. JOHNSON, P. GULHATI, I. ARRIETA, X. WANG, T. GAO, B.M. EVERS ( <i>Galveston, TX, USA</i> ) .....	3185
A Common 9 bp Deletion in the Ataxia-telangiectasia-mutated Gene Is Not Associated with Oral Cancer. S. SPYRIDONIDOU, C. YAPIJAKIS, E. NKENKE, T. TOYOSHIMA, A. VYLLIOTIS, Z. SEREFOGLOU, F.W. NEUKAM, E. PATSOURIS, E. VAIRAKTARIS ( <i>Athens, Greece; Nurnberg, Germany</i> ) .....	3191
Keratinocyte Growth Factor (KGF) Regulates Estrogen Receptor- $\alpha$ (ER- $\alpha$ ) Expression and Cell Apoptosis via Phosphatidylinositol 3-kinase (PI3K)/Akt Pathway in Human Breast Cancer Cells. H.-L. CHANG, Y. SUGIMOTO, S. LIU, L.-S. WANG, Y.-W. HUANG, W. YE, Y.C. LIN ( <i>Columbus, OH, USA</i> ) .....	3191
Methylation Mediated Silencing of TMS1 in Breast Cancer and its Potential Contribution to Docetaxel Cytotoxicity. E. GORDIAN, K. RAMACHANDRAN, R. SINGAL ( <i>Miami, FL, USA</i> ) .....	3207
Antitumor Potential of Three Herbal Extracts against Human Oral Squamous Cell Lines. Q. CHU, K. SATOH, T. KANAMOTO, S. TERAKUBO, H. NAKASHIMA, Q. WANG, H. SAKAGAMI ( <i>Xi'an, P.R. of China; Saitama; Tokyo; Kanagawa, Japan</i> ) .....	3211
The Effects of Sirolimus on Urothelial Lesions Chemically Induced in ICR Mice by BBN. P.A. OLIVEIRA, R. ARANTES-RODRIGUES, C. SOUSA-DINIZ, A. COLAÇO, L. LOURENÇO, L. FELIPE DE LA CRUZ P., V. MOREIRA DA SILVA, J. AFONSO, C. LOPES, L. SANTOS ( <i>Vila Real; Porto; Póvoa do Lanhoso, Portugal; Lugo, Spain</i> ) .....	3221
Enhanced Antitumour Activity of Cyclopentadienyl-substituted Metallocene Dihalides in Human Breast and Colon Cancer Cells. X. STACHTEA, N. KARAMANOS, N. KLOURAS ( <i>Patras, Greece</i> ) .....	3227
Cancer Cell Growth and Extracellular Matrix Remodeling Mechanism of Ascorbate; Beneficial Modulation by <i>P. leucotomos</i> . N. PHILIPS, L. DULAJ, T. UPADHYA ( <i>Teaneck, NJ, USA</i> ) .....	3233
<i>Clinical Studies</i>	
Intrahepatic Cholangiocarcinoma and Hepatitis: Case Study and Literature Review. F. LUH, A. KUEI, P. FANN, P. CHU, Y. YEN ( <i>Duarte, CA, USA</i> ) .....	3239
CEA in Activated Macrophages. New Diagnostic Possibilities for Tumor Markers in Early Colorectal Cancer. D. JAPINK, M.P.G. LEERS, M.N. SOSEF, M. NAP ( <i>Heerlen, The Netherlands</i> ) .....	3245
Elevated <i>ERCC1</i> Gene Expression in Blood Cells Associated with Exposure to Arsenic from Drinking Water in Inner Mongolia. J. MO, Y. XIA, Z. NING, T.J. WADE, J.L. MUMFORD ( <i>Chapel Hill; Triangle Park, NC, USA; Huhhot; Lin He, Inner Mongolia, China</i> ) .....	3253